Cynata Announces Research Collaboration with University of New South Wales to Develop Stem Cell Therapies for Coronary Artery Disease
Melbourne, Australia; 18 June 2018: Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that it has commenced a preclinical research collaboration with UNSW Sydney (the University of New South Wales)…
Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases
Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment has commenced for the first cohort of healthy volunteers Study conducted by leading Australian early phase clinical trial facility Nucleus Network,…
“Medicines Development for Global Health Secures U.S. FDA Approval For Moxidectin For The Treatment Of River Blindness”
MELBOURNE, GENEVA, and NEW YORK Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved moxidectin 8…
Piper Alderman Melbourne has relocated
From 4 June 2018 you will find them at Level 23, 459 Collins Street, Melbourne, 3000 Commencing Monday 4 June 2018, the Melbourne office of Piper Alderman will operate from Level 23, 459 Collins Street, Melbourne. This change will see…
Member news: Success story of a patient on GrunBiotic’s Neurofolin
Member news: Success story of a patient on GrunBiotic’s Neurofolin: https://www.mamamia.com.au/folate-depression/”
AdAlta secures key manufacturing agreements for AD-214
AdAlta secures key manufacturing agreements for AD-214 Please click here for an ASX announcement relating to the execution of key manufacturing agreements for AD-214
Walter and Eliza Hall Institute news: Structure of protein pair provides blueprint for future drugs
Walter and Eliza Hall Institute researchers have visualised for the first time how the protein SOCS1 ‘switches off’ cell signalling to dampen immune responses and block cancer growth. The atomic-level structure of SOCS1 binding to its partner protein…
AusBiotech announces leadership changes
Mr Glenn Cross retires as AusBiotech’s CEO, and Ms Lorraine Chiroiu appointed as new CEO effective early July 2018 Mr Glenn Cross retirement AusBiotech Chairman, Julie Phillips, has tonight announced that Mr Glenn Cross has decided to retire…
$10m in funding awarded to 11 projects to boost health innovation
MTPConnect – the Australian Government’s Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre – and the Minister for Health, the Hon Greg Hunt MP, today announced the first 11 recipients of $10 million investment from the Australian…
Bioforum Data Focused CRO Opens New Melbourne Office
Company provides local services for companies running R&D activities in Australia Bioforum – the Data Focused CRO and the leading Medidata partner in Israel, servicing research and academic institutes, pharma companies, CROs and startups locally and globally for…
Prota Therapeutics partners with world-leading bioscience company, Chr. Hansen
Prota Therapeutics partners with leading global bioscience company, Chr. Hansen, to progress the development of oral immunotherapies to treat food allergies. The partnership will assess the world’s best documented probiotic strain LGG® in a Phase III clinical trial…
Cancer Therapeutics CRC Appoints New CEO
Cancer Therapeutics CRC (CTX), a small molecule oncology drug discovery and development group partnered with some of Australia’s pre-eminent medical research institutions, is pleased to announce the appointment of Brett Carter as Chief Executive Officer. Brett will succeed…
